Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Breast Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 16 articles:
HTML format
Text format



Single Articles


    March 2019
  1. AZAD G, Siddique M, Taylor B, Green A, et al
    Reply to: Relevance of measurement uncertainty for quantitative response assessment of breast cancer bone metastases with (18)F-fluoride.
    J Nucl Med. 2019 Mar 8. pii: jnumed.119.226555. doi: 10.2967/jnumed.119.226555.
    PubMed     Text format    


  2. KUMAR M, Salem K, Michel CJ, Jeffery JJ, et al
    (18)F-Fluoroestradiol Positron Emission Tomography Imaging of Activating Estrogen Receptor Alpha Mutations in Breast Cancer.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.224667. doi: 10.2967/jnumed.118.224667.
    PubMed     Text format     Abstract available


    February 2019
  3. LAFFON E, Marthan R
    Relevance of measurement uncertainty for quantitative response assessment of breast cancer bone metastases with (18)F-fluoride.
    J Nucl Med. 2019 Feb 7. pii: jnumed.119.226092. doi: 10.2967/jnumed.119.226092.
    PubMed     Text format    


    September 2018
  4. ULANER GA, Juarez J, Riedl C, Goldman D, et al
    (18)F-FDG PET/CT for Systemic Staging of Newly Diagnosed Breast Cancer in Men.
    J Nucl Med. 2018 Sep 20. pii: jnumed.118.217836. doi: 10.2967/jnumed.118.217836.
    PubMed     Text format     Abstract available


    July 2018
  5. AZAD G, Siddique MM, Taylor B, Green A, et al
    Does measurement of (18)F-fluoride metabolic flux improve response assessment of breast cancer bone metastases compared with standardised uptake values in (18)F-fluoride PET/CT?
    J Nucl Med. 2018 Jul 24. pii: jnumed.118.208710. doi: 10.2967/jnumed.118.208710.
    PubMed     Text format     Abstract available


  6. SALEM K, Kumar M, Yan Y, Jeffery JJ, et al
    Sensitivity and Isoform Specificity of (18)F-Fluorofuranylnorprogesterone for Measuring Progesterone Receptor Protein Response to Estradiol Challenge in Breast Cancer.
    J Nucl Med. 2018 Jul 20. pii: jnumed.118.211516. doi: 10.2967/jnumed.118.211516.
    PubMed     Text format     Abstract available


    June 2018
  7. KURLAND BF, Oesterreich S
    Heterogeneity in metastatic breast cancer (18)F-fluoroestradiol uptake - clinically actionable, biologically illuminating?
    J Nucl Med. 2018 Jun 14. pii: jnumed.118.214304. doi: 10.2967/jnumed.118.214304.
    PubMed     Text format    


  8. SAH BR, Ghafoor S, Burger IA, Ter Voert EEGW, et al
    Feasibility of (18)F-FDG Dose Reductions in Breast Cancer PET/MRI.
    J Nucl Med. 2018 Jun 7. pii: jnumed.118.209007. doi: 10.2967/jnumed.118.209007.
    PubMed     Text format     Abstract available


    May 2018
  9. PETERSON LM, O'Sullivan J, Wu QV, Novakova-Jiresova A, et al
    Prospective study of serial (18)F-FDG PET and (18)F-fluoride ((18)F-NaF) PET to predict time to skeletal related events, time-to-progression, and survival in patients with bone-dominant metastatic breast cancer.
    J Nucl Med. 2018 May 10. pii: jnumed.118.211102. doi: 10.2967/jnumed.118.211102.
    PubMed     Text format     Abstract available


    April 2018
  10. WU J, Wang S, Zhang X, Teng Z, et al
    (18)F-Alfatide II PET/CT for Identification of Breast Cancer: A Preliminary Clinical Study.
    J Nucl Med. 2018 Apr 26. pii: jnumed.118.208637. doi: 10.2967/jnumed.118.208637.
    PubMed     Text format     Abstract available


  11. GROHEUX D
    Now is the time to use FDG-PET/CT to optimize neoadjuvant treatment in triple negative breast cancer!
    J Nucl Med. 2018 Apr 19. pii: jnumed.118.210922. doi: 10.2967/jnumed.118.210922.
    PubMed     Text format    


    March 2018
  12. NIENHUIS HH, van Kruchten M, Elias SG, Glaudemans AWJM, et al
    ((18))F-fluoroestradiol Tumor Uptake is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients.
    J Nucl Med. 2018 Mar 30. pii: jnumed.117.198846. doi: 10.2967/jnumed.117.198846.
    PubMed     Text format     Abstract available


  13. MONTEMAGNO C, Bacot S, Ahmadi M, Kerfelec B, et al
    Preclinical evaluation of novel mesothelin-specific ligands for SPECT imaging of Triple Negative Breast Cancer.
    J Nucl Med. 2018 Mar 23. pii: jnumed.117.203489. doi: 10.2967/jnumed.117.203489.
    PubMed     Text format     Abstract available


    February 2018
  14. HUMBERT O, Lasserre M, Bertaut A, Fumoleau P, et al
    Pattern of breast cancer blood flow and metabolism, assessed using dual-acquisition (18)FDG PET: correlation with tumor phenotypic features and pathological response to neoadjuvant chemotherapy.
    J Nucl Med. 2018 Feb 9. pii: jnumed.117.203075. doi: 10.2967/jnumed.117.203075.
    PubMed     Text format     Abstract available


    November 2017
  15. ULANER GA, Lyashchenko SK, Riedl C, Ruan S, et al
    First-in-human HER2-targeted imaging using 89Zr-pertuzumab PET/CT: Dosimetry and clinical application in patients with breast cancer.
    J Nucl Med. 2017 Nov 16. pii: jnumed.117.202010. doi: 10.2967/jnumed.117.202010.
    PubMed     Text format     Abstract available


    September 2017
  16. VENEMA CM, Mammatas LH, Schroder CP, van Kruchten M, et al
    Androgen and estrogen receptor imaging in metastatic breast cancer patients as a surrogate for tissue biopsies.
    J Nucl Med. 2017 Sep 14. pii: jnumed.117.193649. doi: 10.2967/jnumed.117.193649.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: